EFTR (eFFECTOR Therapeutics) Marketable Securities: $9.88 Mil (As of Mar. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is eFFECTOR Therapeutics Marketable Securities?

eFFECTOR Therapeutics EFTR Marketable Securities is $9.88 Mil as of Mar. 2024.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. eFFECTOR Therapeutics's Marketable Securities for the quarter that ended in Mar. 2024 was $9.88 Mil.

eFFECTOR Therapeutics's annual Marketable Securities increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($17.60 Mil) but then declined from Dec. 2022 ($17.60 Mil) to Dec. 2023 ($3.50 Mil).

eFFECTOR Therapeutics  (OTCPK:EFTR) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

eFFECTOR Therapeutics Marketable Securities Related Terms

eFFECTOR Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for eFFECTOR Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

eFFECTOR Therapeutics Marketable Securities Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Marketable Securities
0.00 0.00 17.60 3.50

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.70 10.31 12.39 3.50 9.88

eFFECTOR Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $9.88 Mil mean?
eFFECTOR Therapeutics (EFTR) has a Marketable Securities of $9.88 Mil as of Mar. 2024. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on eFFECTOR Therapeutics and its competitors.
Is eFFECTOR Therapeutics' Marketable Securities too high?
eFFECTOR Therapeutics' current Marketable Securities is $9.88 Mil.
How does eFFECTOR Therapeutics' Marketable Securities compare to NTBLQ and MTEM?
eFFECTOR Therapeutics' Marketable Securities of $9.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on eFFECTOR Therapeutics and its competitors. eFFECTOR Therapeutics's current Marketable Securities is $9.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is eFFECTOR Therapeutics stock overvalued right now?
eFFECTOR Therapeutics (EFTR) has a current Marketable Securities of $9.88 Mil. The current Marketable Securities is $9.88 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For eFFECTOR Therapeutics (EFTR), the current Marketable Securities is $9.88 Mil as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

eFFECTOR Therapeutics Business Description

Address 142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).